Small-animal PET imaging of tau pathology with 18F-THK5117 in 2 transgenic mouse models

Journal of Nuclear Medicine

Volumn 57, Issue 5, 2016, Pages 792-798

  Brendel, Matthias ^a   Jaworska, Anna ^b   Probst, Federico ^a   Overhoff, Felix ^a   Korzhova, Viktoria ^b   Lindner, Simon ^a   Carlsen, Janette ^a   Bartenstein, Peter ^a,c   Harada, Ryuichi ^d   Kudo, Yukitsuka ^d   Haass, Christian ^a,b,c   Van Leuven, Fred ^e   Okamura, Nobuyuki ^d   Herms, Jochen ^b,c   Rominger, Axel ^a,c  

^a UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c Technische Universität München Munich Cluster for Systems Neurology   (Germany)

^d TOHOKU UNIVERSITY   (Japan)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

18F THK5117; Alzheimer s disease; Small animal PET; Tauopathy; Transgenic mice

Indexed keywords

QUINOLINE DERIVATIVE; TAU PROTEIN; THK 5117 F 18; UNCLASSIFIED DRUG; 6-((3-FLUORO-2-HYDROXY)PROPOXY)-2-(4-METHYLAMINOPHENYL)QUINOLINE; ANILINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN STEM; CEREBELLUM; CONTROLLED STUDY; EX VIVO STUDY; GOLD STANDARD; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NERVE CELL; NEUROFIBRILLARY TANGLE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETRIC TEST; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; SENSITIVITY ANALYSIS; TAUOPATHY; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; PHOSPHORYLATION; PROCEDURES;

ANILINE COMPOUNDS; ANIMALS; AUTORADIOGRAPHY; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; POSITRON-EMISSION TOMOGRAPHY; QUINOLINES; RADIOCHEMISTRY; TAU PROTEINS;

EID: 84966762536     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.163493     Document Type: Article

References (28)

1. Ziegler-Graham K, Brookmeyer R, Johnson E, Arrighi HM. Worldwide variation in the doubling time of Alzheimer's disease incidence rates. Alzheimers Dement. 2008;4:316-323.
2. Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement. 2012;8:S1-S68.
3. Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol (Berl). 2009;118:5-36.
4. Denk F, Wade-Martins R. Knock-out and transgenic mouse models of tauopathies. Neurobiol Aging. 2009;30:1-13.
5. Hall AM, Roberson ED. Mouse models of Alzheimer's disease. Brain Res Bull. 2012;88:3-12.
6. Teipel SJ, Buchert R, Thome J, Hampel H, Pahnke J. Development of Alzheimerdisease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression. Prog Neurobiol. 2011;95:547-556.
7. Zimmer ER, Leuzy A, Bhat V, Gauthier S, Rosa-Neto P. In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals. Transl Neurodegener. 2014;3:6.
8. Zimmer ER, Parent MJ, Cuello AC, Gauthier S, Rosa-Neto P. MicroPET imaging and transgenic models: A blueprint for Alzheimer's disease clinical research. Trends Neurosci. 2014;37:629-641.
9. Brendel M, Jaworska A, Griessinger E, et al. Cross-sectional comparison of small animal [18F]-florbetaben amyloid-PET between transgenic AD mouse models. PLoS One. 2015;10:e0116678.
10. Rominger A, Brendel M, Burgold S, et al. Longitudinal assessment of cerebral beta-amyloid deposition in mice overexpressing Swedish mutant betaamyloid precursor protein using 18F-florbetaben PET. J Nucl Med. 2013;54: 1127-1134.
11. Snellman A, Lopez-Picon FR, Rokka J, et al. Longitudinal amyloid imaging in mouse brain with 11C-PIB: Comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. J Nucl Med. 2013;54:1434-1441.
12. Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094-1108.
13. Okamura N, Furumoto S, Harada R, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54:1420-1427.
14. Villemagne VL, Okamura N. In vivo tau imaging: Obstacles and progress. Alzheimers Dement. 2014;10:S254-S264.
15. Tago T, Furumoto S, Okamura N, et al. Synthesis and preliminary evaluation of 2-arylhydroxyquinoline derivatives for tau imaging. J Labelled Comp Radiopharm. 2014;57:18-24.
16. Dorr A, Sled JG, Kabani N. Three-dimensional cerebral vasculature of the CBA mouse brain: A magnetic resonance imaging and micro computed tomography study. Neuroimage. 2007;35:1409-1423.
17. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840.
18. Constantinescu CC, Mukherjee J. Performance evaluation of an Inveon PET preclinical scanner. Phys Med Biol. 2009;54:2885-2899.
19. Rominger A, Mille E, Boning G, et al. alpha2-adrenergic drugs modulate the binding of [18F]fallypride to dopamine D2/3 receptors in striatum of living mouse. Synapse. 2010;64:654-657.
20. Santacruz K, Lewis J, Spires T, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476-481.
21. Fodero-Tavoletti MT, Okamura N, Furumoto S, et al. 18F-THK523: A novel in vivo tau imaging ligand for Alzheimer's disease. Brain. 2011;134:1089-1100.
22. Shah M, Catafau AM. Molecular Imaging Insights into Neurodegeneration: Focus on Tau PET Radiotracers. J Nucl Med. 2014;55:871-874.
23. Fodero-Tavoletti MT, Furumoto S, Taylor L, et al. Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies. Alzheimers Res Ther. 2014;6:11.
24. Crespo-Biel N, Theunis C, Borghgraef P, et al. Phosphorylation of protein tau by GSK3beta prolongs survival of bigenic Tau.P301LxGSK3beta mice by delaying brainstem tauopathy. Neurobiol Dis. 2014;67:119-132.
25. Lemoine L, Saint-Aubert L, Marutle A, et al. Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue. Acta Neuropathol Commun. 2015;3:40.
26. Allen B, Ingram E, Takao M, et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci. 2002;22:9340-9351.
27. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82:239-259.
28. Brendel M, Jaworska A, Herms J, et al. Amyloid-PET predicts inhibition of de novo plaque formation upon chronic gamma-secretase modulator treatment. Mol Psychiatry. 2015;20:1179-1187.